Long-term use of albuterol side effects
Pro Research Analysisby 
Searched over 200M research papers
Long-Term Use of Albuterol: Side Effects and Safety
Introduction to Albuterol and Its Usage
Albuterol is a widely used beta2-adrenergic agonist that helps relax airway smooth muscles, making it a common treatment for asthma and other respiratory conditions. It is available in various forms, including metered-dose inhalers (MDIs), oral tablets, and nebulizer solutions . While effective in managing acute bronchospasm, concerns have been raised about the long-term safety of regular albuterol use.
General Safety of Long-Term Albuterol Use
Adverse Events and Tolerability
Several studies have investigated the safety profile of long-term albuterol use. A study comparing levalbuterol and racemic albuterol over 52 weeks found that both were well tolerated, with similar rates of adverse events (72.0% for levalbuterol and 76.8% for racemic albuterol) . Serious adverse events and discontinuations due to adverse events were low (<15%) and comparable between the two groups . Another study comparing HFA albuterol to CFC albuterol over one year also reported similar safety profiles, with no serious adverse events attributed to the study drugs .
Specific Side Effects
Long-term albuterol use can lead to several dose-related side effects. These include metabolic effects such as decreased plasma potassium, phosphate, calcium, and magnesium levels, and increased plasma glucose, insulin, renin, lactate, and ketone levels . Cardiovascular effects like peripheral vasodilation, decreased systemic and pulmonary vascular resistance, increased pulse pressure, and tachycardia have also been noted . Additionally, skeletal muscle tremors are a common side effect, particularly with parenteral administration .
Impact on Lung Function and Efficacy
Pulmonary Parameters
Long-term studies have shown that regular use of albuterol does not lead to deterioration in lung function. In a year-long study, the mean percentage of predicted FEV1 improved after dosing and remained stable for both levalbuterol and racemic albuterol groups . Similarly, another study found that predose FEV1 increased slightly over 12 months for both HFA and CFC albuterol, although bronchodilator efficacy decreased over time .
Efficacy in Special Populations
In patients with late-onset Pompe disease, extended-release albuterol showed potential benefits as an adjunctive therapy. The study reported improvements in forced vital capacity, forced expiratory volume, and performance in the six-minute walk test, with no serious adverse events related to albuterol . This suggests that albuterol can be beneficial in specific patient populations when used alongside other treatments.
Conclusion
Overall, long-term use of albuterol appears to be well tolerated with a manageable safety profile. While some dose-related side effects are noted, they are generally mild and less prominent with aerosol administration. Regular monitoring and appropriate dosing can help mitigate these risks, making albuterol a viable long-term treatment option for managing chronic respiratory conditions.
Sources and full results
Most relevant research papers on this topic